Floatz logo

Necitumumab

Metastatic Lung Non-Small Cell Carcinoma

Jonsson Comprehensive Cancer Centermonoclonal_antibodyPhase 3Active
BBB
76/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
69/ 100
Competitive Position
89/ 100

Competitive context

1205 Active assets in the Metastatic Lung Non-Small Cell Carcinoma cohort.

Asset / SponsorPhaseRating
Zorifertinib
Alpha Biopharma (Jiangsu) Co., Ltd.
Phase 2/3BBB
Glumetinib
Shanghai JMT-Bio Inc.
Phase 3BBB
Zoledronate
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 4BBB
Icotinib
The First Affiliated Hospital of Guangzhou Medical University
Phase 4BBB
d-0316
Betta Pharmaceuticals Co., Ltd.
Phase 2/3BBB

View all 50 →

Same molecule, other indications

Necitumumab is also rated in:

Squamous Cell Lung CancerDormant
BB
Indicative ·
64 / 100
View asset →
non-small cell squamous lung carcinomaDormant
B
Indicative ·
57 / 100
View asset →
Malignant Solid TumorDormant
B
Indicative ·
57 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →